Hepion Pharmaceuticals Inc expected to post a loss of $2.68 a share - Earnings Preview

Hepion Pharmaceuticals

04/11/2023 03:04

* Hepion Pharmaceuticals Inc  HEPA.OQ   HEPA.O  is expected
to report  results 
    * 
    * ​Refinitiv's mean analyst estimate for Hepion
Pharmaceuticals
Inc is for a loss of $2.68 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Hepion
Pharmaceuticals Inc is $26​, above​ its last closing price
of $4.25. ​​​

This summary was machine generated November 4 at 03:03 GMT.  All
figures in US dollars  unless otherwise stated